Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives
AssigneeCephalon, Inc.
InventorsMatthew A. Curry, Bruce D. Dorsey, Benjamin J. Dugan, Diane E. Gingrich, Eugen F. Mesaros, Karen L. Milkiewicz
Life of this patent
Estimating the term…
Abstract
This application relates, in part, to compounds of the general Formula I and/or salts thereof, wherein X, R1A, R1B, R2, R3, R4, and R5 are as defined herein. The application also relates to compositions and methods of inhibiting at least JAK2 in subjects in recognized need thereof for the treatment of diseases or disorders for which inhibition of at least JAK2 is indicated.
Claims6
A method of inhibiting JAK2 in a subject in recognized need thereof, comprising administering a compound of Formula V:
- or a salt thereof, wherein:
- R3A, R4A, and R5A are each independently selected from H, OH, CN, NO2, halogen, (C1-C8)alkyl, (C1-C8)alkoxy, halo(C1-C4)alkyl, and halo(C1-C4)alkoxy;
- R7A is selected from H and (C1-C8)alkyl;
- R8 is selected from SO2R7A, NR7ACOR7A, (C2-C8)alkyl, (C1-C8)alkoxy, halo(C2-C4)alkyl, halo(C1-C4)alkoxy, (C3-C14)cycloalkyl, (C3-C14)cycloalkyloxy, (C3-C14)cycloalkyl(C1-C4)alkyl, (C3-C14)cycloalkyl(C1-C4)alkoxy, (C6-C10)aryl, (C6-C10)aryloxy, (C6-C10)aryl(C1-C4)alkyl, (C6-C10)aryl(C1-C4)alkoxy, (C2-C14)heterocycloalkyl, (C2-C14)heterocycloalkyloxy, (C2-C14)heterocycloalkyl(C1-C4)alkyl, (C2-C14)heterocycloalkyl(C1-C4)alkoxy, (C2-C9)heteroaryl, (C2-C9)heteroaryloxy, (C2-C9)heteroaryl(C1-C4)alkyl, and (C2-C9)heteroaryl(C1-C4)alkoxy, wherein each of the aforementioned groups may be optionally substituted with between one to four substituents;
- R9 is selected from SO2R7A, POR7AR7A, NR7ASO2R7A, halo(C1-C4)alkyl, halogen, or (C2-C14)heterocycloalkyl optionally substituted with between one to four substituents;
- R10 is selected from H and (C1-C4)alkyl optionally substituted with SO2(C1-C4)alkyl;
- g is selected from 0, 1, 2, or 3;
- and
- wherein said optional substituents are each independently selected from OH, CN, oxo, NO2, halogen, (C1-C8)alkyl, (C1-C8)alkoxy, hydroxy(C1-C4)alkyl, halo(C1-C4)alkyl, halo(C1-C4)alkoxy, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C4)alkyl, (C3-C14)cycloalkyloxy, (C3-C14)cycloalkyl(C1-C4)alkoxy, NR7AR7A, (C1-C4)alkyl-NRAR7A, (C6-C10)aryl, (C6-C10)aryl(C1-C4)alkyl, (C6-C10)aryloxy, (C6-C10)aryl(C1-C4)alkoxy, SO2R7A, (C1-C4)alkyl-SO2R7A, (C1-C4)alkyl-C(O)NR7AR7A, C(O)NR7AR7A, (C1-C4)alkyl-SO2NR7AR7A, SO2NR7AR7A, (C2-C14)heterocycloalkyl, (C2-C14)heterocycloalkyloxy, (C2-C14)heterocycloalkyl(C1-C4)alkyl, (C2-C14)heterocycloalkyl(C1-C4)alkoxy, (C2-C9)heteroaryl, (C2-C9)heteroaryloxy, (C2-C9)hetero aryl(C1-C4)alkyl, (C2-C9)heteroaryl(C1-C4)alkoxy, COR7A, (C1-C4)alkyl-COR7A, NR7ACOR7A, (C1-C4)alkyl-NR7ACOR7A, NR7ASO2R7A, (C1-C4)alkyl-NR7ASO2R7A, OSO2R7A, (C1-C4)alkyl-OSO2R7A, POR7AR7A, (C1-C4)alkyl-POR7AR7A, CO2R7A or (C1-C4)alkyl-CO2R7A,
- wherein said compound or salt thereof preferentially inhibits the JAK2 enzyme in vitro.
A method of treating a disease or disorder for which inhibition of at least JAK2 is indicated, comprising administering to subject in recognized need thereof a compound of Formula V
- or a salt thereof, wherein:
- R3A, R4A, and R5A are each independently selected from H, OH, CN, NO2, halogen, (C1-C8)alkyl, (C1-C8)alkoxy, halo(C1-C4)alkyl, and halo(C1-C4)alkoxy;
- R7A is selected from H and (C1-C8)alkyl;
- R8 is selected from SO2R7A, NR7ACOR7A, (C2-C8)alkyl, (C1-C8)alkoxy, halo(C2-C4)alkyl, halo(C1-C4)alkoxy, (C3-C14)cycloalkyl, (C3-C14)cycloalkyloxy, (C3-C14)cycloalkyl(C1-C4)alkyl, (C3-C14)cycloalkyl(C1-C4)alkoxy, (C6-C10)aryl, (C6-C10)aryloxy, (C6-C10)aryl(C1-C4)alkyl, (C6-C10)aryl(C1-C4)alkoxy, (C2-C14)heterocycloalkyl, (C2-C14)heterocycloalkyloxy, (C2-C14)heterocycloalkyl(C1-C4)alkyl, (C2-C14)heterocycloalkyl(C1-C4)alkoxy, (C2-C9)heteroaryl, (C2-C9)heteroaryloxy, (C2-C9)heteroaryl(C1-C4)alkyl, and (C2-C9)heteroaryl(C1-C4)alkoxy, wherein each of the aforementioned groups may be optionally substituted with between one to four substituents;
- R9 is selected from SO2R7A, POR7AR7A, NR7ASO2R7A, halo(C1-C4)alkyl, halogen, or (C2-C14)heterocycloalkyl optionally substituted with between one to four substituents;
- R10 is selected from H and (C1-C4)alkyl optionally substituted with SO2(C1-C4)alkyl;
- g is selected from 0, 1, 2, or 3;
- and
- wherein said optional substituents are each independently selected from OH, CN, oxo, NO2, halogen, (C1-C8)alkyl, (C1-C8)alkoxy, hydroxy(C1-C4)alkyl, halo(C1-C4)alkyl, halo(C1-C4)alkoxy, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C4)alkyl, (C3-C14)cycloalkyloxy, (C3-C14)cycloalkyl(C1-C4)alkoxy, NR7AR7A, (C1-C4)alkyl-NR7AR7A, (C6-C10)aryl, (C6-C10)aryl(C1-C4)alkyl, (C6-C10)aryloxy, (C6-C10)aryl(C1-C4)alkoxy, SO2R7A, (C1-C4)alkyl-SO2R7A, (C1-C4)alkyl-C(O)NR7AR7A, C(O)NR7AR7A, (C1-C4)alkyl-SO2NR7AR7A, SO2NR7AR7A, (C2-C14)heterocycloalkyl, (C2-C14)heterocycloalkyloxy, (C2-C14)heterocycloalkyl(C1-C4)alkyl, (C2-C14)heterocycloalkyl(C1-C4)alkoxy, (C2-C9)heteroaryl, (C2-C9)heteroaryloxy, (C2-C9)hetero aryl(C1-C4)alkyl, (C2-C9)heteroaryl(C1-C4)alkoxy, COR7A, (C1-C4)alkyl-COR7A, NR7ACOR7A, (C1-C4)alkyl-NR7ACOR7A, NR7ASO2R7A, (C1-C4)alkyl-NR7ASO2R7A, OSO2R7A, (C1-C4)alkyl-OSO2R7A, POR7AR7A, (C1-C4)alkyl-POR7AR7A, CO2R7A or (C1-C4)alkyl-CO2R7A,
- wherein said compound or salt thereof preferentially inhibits the JAK2 enzyme in vitro.
Dependencies are inferred from the claim text.